PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Addict Dis. Author manuscript; available in PMC 2010 September 9.
Published in final edited form as:
J Addict Dis. 2007; 26(4): 41–54.
doi:  10.1300/J069v26n04_06
PMCID: PMC2936493
NIHMSID: NIHMS167664

TREATMENT OPTIONS FOR SLEEP DISTURBANCES DURING ALCOHOL RECOVERY

J. Todd Arnedt, Ph.D.,1 Deirdre A. Conroy, Ph.D.,2 and Kirk J. Brower, M.D., FASAM2

Abstract

Sleep disturbances are extremely common in the early stages of recovery from alcohol dependence and may persist for several months despite continued abstinence. Studies indicate that sleep disturbances independently increase the risk for relapse to alcohol, suggesting that targeting these problems during recovery may support continued abstinence. However, there is limited information in the addiction literature about available and effective treatments for sleep disturbances in recovering alcoholic patients. The primary goals of this article are to describe the phenomenology of sleep disturbances during recovery from alcohol dependence, to outline the evidence linking sleep problems with alcohol relapse, and to describe available pharmacological and nonpharmacological treatment options, including the evidence regarding their efficacy in recovering alcoholic patients. Recommendations for future research are provided along with special considerations for treating insomnia in this population, including avoiding cross-dependent sedatives, such as benzodiazepines and benzodiazepine receptor agonists (BzRAs).

Keywords: alcohol, alcoholism, sleep, insomnia, treatment, pharmacological, nonpharmacological, cognitive-behavioral treatment

Insomnia is a complaint of difficulties falling asleep, frequent and/or prolonged awakenings, and/or consistently unrefreshing sleep that occurs despite adequate sleep opportunity. Insomnia is exceedingly common: as many as 1/3 of adults report experiencing persistent insomnia symptoms during the year.14 Insomnia symptoms persisting for more than one month that are associated with daytime impairment and/or psychological distress define an insomnia disorder, which occurs in one in ten individuals. Persistent insomnia is associated with wide ranging adverse consequences, including decreased quality of life, increased risk for psychiatric disturbances, increased work absenteeism, and poor interpersonal functioning.1,2,5,6 Among patients in recovery from alcohol dependence, insomnia complaints are especially frequent and may persist for weeks to months post-abstinence.714 Of particular importance, untreated insomnia may interfere with recovery from the primary alcohol addiction and contribute to relapse within the first several months of recovery.12,15,16 Thus, treating insomnia in recovering alcoholic patients may aid in their recovery and support continued abstinence.

Despite the putative importance of sleep in the recovery process, there is limited information in the addiction literature about appropriate treatment options for insomnia during recovery. This may exist for a variety of reasons: clinicians assume that co-morbid sleep problems will remit with treatment of the primary alcohol condition; sleep problems are de-emphasized as relatively less important in the early stages of treatment for alcohol dependence; or physicians may be reluctant to address sleep problems due to concerns about sleep medication addiction and limited awareness of other treatment options. This article has three primary goals: (1) to describe the nature and course of insomnia and sleep disturbances among recovering alcoholics; (2) to outline the evidence for the relationship between sleep variables and relapse; and (3) to describe available sleep treatments and the evidence regarding their use in alcoholic patients.

What are the rates of co-occurrence of insomnia and alcohol problems?

Alcohol is used by more than one in ten individuals as a hypnotic agent to self-medicate sleep problems.17 Among community samples, insomnia increases the likelihood of developing alcohol problems. The Epidemiologic Area Catchment (ECA) study, for example, found that the 6-month prevalence of DSM-III-defined alcohol abuse and dependence was 7.0% among those who responded yes to the question “Have you ever had a period of two weeks or more when you had trouble falling asleep, staying asleep or waking up too early?” compared to only 3.8% among those who responded no.5 Those who reported insomnia in the past year but no psychiatric condition were more than twice as likely to develop alcohol abuse over the subsequent year compared to those without either condition at baseline.18 A similar level of risk was found between “sleep disturbances because of worry” and alcohol problems 12 to 15 years later after controlling for select demographic (e.g., age of first intoxication) and psychiatric variables (OR=2.32, 95% CI=1.31–4.09).19 Chronic dependence was more commonly associated with insomnia than no history of dependence at 13-year follow-up.20 A recent study in adolescents found that maternal-rated sleep problems at 3 to 5 years of age (Child Behavior Checklist – Parent Version) in 257 boys from a community-recruited sample of high-risk families predicted early onset of any alcohol use by 12 to 14 years of age. This relationship was not mediated by attention problems, anxiety/depression, or aggression.21 Thus, insomnia may increase the risk for the development of alcohol problems and may contribute to initial substance use.

At least seven studies have evaluated the rates of insomnia among alcoholic patients in treatment. In an early observational study, 58% of a sample of 40 alcoholic male inpatients developed insomnia during the first 6 days of acute alcohol withdrawal.7 Using single item rating scales, nearly three-quarters of 82 inpatients endorsed sleep problems immediately after detoxification11 and slightly more than one-third of 294 outpatients reported sleep disturbance during the first month of abstinence.8 Using a more rigorous standardized questionnaire, Caetano et al. found that ⅔ of a sample of more than 600 men admitted to detoxification and residential treatment programs endorsed insomnia as a withdrawal symptom.10 Only two studies have used validated sleep disturbance scales to assess insomnia among alcoholic patients in recovery. One found that 61% of a heterogeneous sample of inpatient and outpatient alcoholics reported insomnia during the six months preceding treatment, as measured by a subset of items from the Sleep Disorders Questionnaire;12 the other found that 91% of inpatient alcoholics scored above the clinical cutoff on the Pittsburgh Sleep Quality Index after one week of abstinence.14

Taken together, these seven studies suggest higher co-morbidity for insomnia symptoms and alcoholism than in the general population,5,18 with comparable rates to more widely studied psychiatric subgroups (e.g., depression).22 Prevalence estimates vary widely because insomnia was rarely operationally defined, few studies used validated instruments, none established whether insomnia was a pre-existing condition or developed in the context of alcohol dependence, and sample characteristics and the assessment time frame varied from study to study. It was also not always clearly stated that subjects were abstinent from cross-tolerant sedatives in addition to alcohol. Studies also failed to differentiate insomnia symptoms from an insomnia disorder, which is characterized by the additional burden of daytime impairment and/or psychological distress attributable to the sleep problems. Insomnia disorders are more likely to have a chronic course, to require independent treatment, and may contribute more directly to relapse during alcohol recovery. Large-scale epidemiological studies with validated measures and good operational definitions of insomnia are clearly warranted to establish the incidence and prevalence of insomnia in the alcoholic population and its clinical course in relation to the alcohol disorder.

What is the course of recovery of insomnia and other sleep disturbances during abstinence?

Only a handful of studies have assessed the persistence of insomnia during alcohol recovery. In an early uncontrolled study, Alling and colleagues23 reported that insomnia symptoms in 56 recently abstinent alcoholic patients persisted for approximately 5 weeks. Cohn and colleagues14 administered the Pittsburgh Sleep Quality Index (PSQI),24 a validated instrument that measures general sleep disturbance, to 57 alcoholic inpatients (19 women, age range 23–69 years) monthly for 12 weeks. Despite improvement, PSQI total scores remained above the clinical cutoff of 5, suggesting persistent sleep disturbances: 11.7±4.3 at baseline, 9.1±4.4 at 4 weeks, 7.3±4.2 at 8 weeks, and 5.7 ±3.3 at 12 weeks. The subscales for sleep quality, sleep latency, and habitual sleep efficiency, which are most reflective of insomnia, showed no improvements.14 Another study found recovery of total PSQI scores by six months with continued abstinence (7.1±3.4 at baseline vs. 4.8±2.4 at 6 months).25

Several studies have evaluated sleep disturbances in abstinent alcoholics using overnight polysomnography (PSG). PSG provides objective information about sleep quantity and quality that are summarized in measures of sleep continuity, sleep architecture, and respiratory or other physiological parameters (e.g., limb movements). Sleep continuity refers to measures of sleep initiation and maintenance (i.e., insomnia) and include sleep latency (the length of time from “lights out” to sleep onset), the number and duration of nighttime awakenings, total sleep time, and sleep efficiency (time asleep/time in bed*100). Sleep architecture refers to the macrostructure of sleep that is divided into two separate states: Non Rapid Eye Movement (NREM; Stages 1, 2, 3, and 4) and Rapid Eye Movement (REM) sleep. Sleep architecture differences may be less obvious to patients than periods of extended wakefulness at night (sleep discontinuity), but they may relate to next-day reports of sleep quality and daytime functioning.

In young adults without sleep complaints, sleep latency occurs within 20 minutes, 75% of the night is spent in NREM sleep (15–20% in Stages 3 and 4 combined, also called “deep” or “slow wave” sleep (SWS), and sleep alternates between NREM and REM in roughly 90-minute cycles.26 With increasing age, decreases in total sleep time, sleep efficiency, percentage of SWS and REM, and REM latency (the elapsed time between sleep onset and the first appearance of REM sleep) are evident; by contrast, there are increases in sleep latency, the percentage of Stages 1 and 2 (light sleep), and time awake during the night.27

Middle-aged alcoholic adults demonstrate severely disrupted sleep continuity and architecture during acute withdrawal (first 1–2 weeks), subacute withdrawal (weeks 2 to 8), and with sustained abstinence. Early largely uncontrolled studies in male alcoholics during the first few months of recovery reported increased sleep fragmentation (frequent awakenings, stage changes, and movements during sleep), a substantial reduction of SWS, particularly Stage 4, and increased REM sleep, due to shortened REM latency and REM-NREM cycles.9,2832 More recent well-controlled studies largely supported these earlier findings, but continued to include only male subjects so the findings may not generalize to female alcoholics. Gillin and colleagues,33 for example, compared the sleep of 31 middle-aged male DSM-III-defined “primary” alcoholics (no pre-existing major psychiatric disorder prior to the onset of alcoholism) in the first two weeks of recovery with 34 healthy male controls. Compared to the controls, sleep latency was increased (24 ± 15 vs. 10 ± 8 minutes) and total sleep time (334 ± 51 vs. 368 ± 48 minutes) and SWS percentage (3.6 ± 6.1 vs. 8.1 ± 8.0 %) were decreased in the alcoholic group. Other studies have reported decreased sleep efficiency and REM latency, and increases in the percentage of Stage 1, the number of awakenings and stage shifts during the night, and REM density (number of eye movements in REM sleep per REM episode) in alcoholic patients compared with controls.25,34,35 The effects on REM sleep typically persist during subacute withdrawal, particularly in alcoholics with depression.2932 Sleep disturbances during the first few months of recovery are more severe in alcoholic patients who are older,36 of African American ethnicity,37 and who have co-morbid depression.38 Indeed, the sleep of non-depressed alcoholics in early recovery may be even more disturbed than the sleep of depressed non-alcoholic patients.35

Longitudinal studies of sleep in alcoholics beyond subacute withdrawal are largely lacking, although the available data suggest that sleep remains grossly disturbed with continued abstinence. In 6- and 12-month PSG evaluations of 11 (28%) abstinent subjects, Gann and colleagues25 reported continued abnormalities in sleep continuity and sleep architecture despite subjectively-rated sleep improvements. Two longitudinal studies evaluated the sleep of male alcoholic veteran inpatients with PSG follow-ups at 2 to 3 weeks, 3 to 6 months, 9 to 15 months, and 2 years post-abstinence.39,40 Despite the methodological differences, some consistent findings emerged. Most measures of sleep continuity (total sleep time, sleep efficiency, sleep latency) and sleep architecture improved in those who remained abstinent during the first year, but increased fragmentation/arousals from sleep, elevated stage changes, and REM disruptions persisted even after two years. These findings need to be interpreted with extreme caution, however, in light of the low retention rates: only 5 of the original 48 patients were evaluated at final follow-up in the first study39 and 4 of 29 were studied at 27 months in the other.40

What role do sleep disturbances play in alcohol relapse?

Five published studies examined whether subjective sleep disturbances increased the likelihood of relapse. In an early observational study, Skoloda and colleagues41 reported that alcoholic inpatients with disturbed sleep and difficulty falling asleep were more likely to relapse by 4 weeks. Two more recent studies15,42 extended these early findings to a 3–5 month follow-up. In one of these studies, 32 of 58 (62%) alcohol dependent subjects who completed an inpatient detoxification program relapsed by 12 weeks.15 Among the clinical and demographic variables collected, only the item ”It takes me a long time to fall asleep” on the Nottingham Health Profile (NHP) questionnaire differentiated relapsers from abstainers. These results supported earlier findings that relapse was most strongly related to the sleep subscores on the NHP.42 Similarly, Brower and colleagues16 reported that alcoholic patients who relapsed by 5 months post-treatment were more likely to report difficulty falling asleep and abnormal sleep than patients who remained abstinent. In a follow-up study, 60% (28/47) of alcoholic patients who reported insomnia in the 6 months prior to quitting alcohol, compared to 30% (8/27) who did not, relapsed after 5 months. After controlling for alcohol dependence and depression severity, baseline insomnia was the only significant predictor of relapse.43

Objective sleep architecture (SWS and REM) and sleep continuity (sleep latency, total sleep time, sleep efficiency) variables have also been studied as potential predictors of relapse.44 Reduced SWS percentage at baseline was implicated in early studies,45,46 but these findings were only partially replicated in a larger sample.16 Gillin and colleagues47 found that increased “REM pressure”—a composite of short REM latency, increased REM percentage, and increased REM density (a measure of eye movement activity during sleep)—at the time of admission to a VA inpatient program correctly predicted relapse in 80% of non-depressed alcoholics at 3-month follow-up. These findings were replicated in one study with a 6-month follow-up that used a cholinergic REM induction test to probe for REM sleep abnormalities.25 Other studies have reported that short REM latency16 and increased REM density48 predicted relapse by 5 months, and in both cases sleep continuity measures (increased sleep latency and reduced total sleep time) were also strongly predictive.16,48 Objective predictors of drinking status at 27 months in the only long-term study were elevated sleep onset latency and decreased sleep efficiency.40

The evidence to date suggests that subjective and objective sleep continuity variables (insomnia) are robust predictors of relapse during recovery from alcohol dependence. On the other hand, the relationship between relapse and sleep architecture variables remains to be fully elucidated. Targeting insomnia during recovery from alcohol dependence may thus improve treatment outcome for the alcoholic patient.

What options exist for treating insomnia in alcoholic patients?

A number of effective pharmacological and nonpharmacological treatment options exist to manage insomnia. Most have been evaluated in non-alcoholic insomnia patients so their efficacy in alcoholic patients is uncertain. Moreover, treating insomnia in the alcoholic patients requires special consideration because of the abuse history and potential for overdose with some pharmacological agents when mixed with alcohol. Clinical guidelines have been recommended for addressing insomnia complaints in early recovery.43 Good sleep practices should be discussed with all recovering alcoholic patients, but adjunctive insomnia treatment should be initiated if sleep problems persist beyond one month and are accompanied by daytime impairment and/or psychological distress.

Pharmacological treatments for insomnia

There are numerous hypnotic medications currently on the market for treating insomnia in nonalcoholic patients. A recent postal survey of addiction treatment specialists, however, revealed reticence in prescribing hypnotic medications to alcoholic patients with insomnia: only 64% of 311 respondents reported offering pharmacological treatment to a recovering alcoholic patient with insomnia and only 22% offered medication to more than half of these patients.49 When a medication was prescribed, trazodone was the preferred hypnotic followed by other sedating antidepressants and antihistamines despite limited evidence of their efficacy in this population. Below, we outline the most commonly available hypnotic medications and their efficacy in alcoholic patients.

Benzodiazepines and benzodiazepine receptor agonists (BzRAs)

Benzodiazepines and other benzodiazepine receptor agonists (e.g., zolpidem) are safe, efficacious, sedative-hypnotics and often the medications of choice for treating transient insomnia in nonalcoholic patients.50 They also may have beneficial effects on sleep during subacute alcohol withdrawal.51 Although the potential for abusing sedative-hypnotics in most patients is low,52 alcoholic patients are regarded as having an increased risk for sedative-hypnotic abuse.5355 Accordingly, most addiction treatment specialists recommend against the use of sedative-hypnotics in alcoholic patients (except for benzodiazepines during acute alcohol withdrawal), because of their abuse potential, withdrawal effects, rebound insomnia, and potential for overdose when mixed with alcohol.5659 Moreover, benzodiazepines suppress SWS, shift EEG activity to higher frequencies (signaling more arousal), and reduce homeostatic sleep drive.60

Anticonvulsants

The potential uses of anticonvulsants for treating alcohol dependence have recently been reviewed.61 They have the obvious advantage of not lowering seizure threshold in alcoholics, a population already at risk for seizures. Kindling and sensitization have been suggested as mechanisms that contribute to protracted withdrawal symptoms such as craving. The anti-kindling effects of anticonvulsants may be important in their potential to prevent relapse. At least two anticonvulsants – carbamazepine and gabapentin – have been studied specifically for their effects on sleep in alcoholics. Carbamazepine was found in one study to be superior to lorazepam for treating sleep disturbance associated with acute alcohol withdrawal.62 Gabapentin has the advantages of sleep promotion, non-liver metabolism, non-interference with metabolism or excretion of other medications, and it does not require blood monitoring for therapeutic concentrations, hepatotoxicity, and hematological toxicity. Furthermore, it has a favorable side effects profile and no known abuse potential, and is not protein-bound. It exerts its CNS effects by binding to alpha-2-delta receptors, resulting in voltage-sensitive calcium channel inhibition.63

In two studies, gabapentin improved the sleep of recovering alcoholic patients.6466 Karam-Hage and Brower64 used gabapentin (mean dose 953 mg/day) to treat 15 of 17 consecutively evaluated abstinent alcoholic patients with persistent insomnia of at least four weeks in an open label study. Self-reported sleep quality improved over 4–6 weeks of treatment and all but two patients remained abstinent. Nightly gabapentin (mean dose 888 ± 418 mg/day) for 4–6 weeks was also found to improve scores on the Sleep Problems Questionnaire (SPQ)67 more than trazodone (mean dose 105 ± 57 mg).65 Patients receiving gabapentin were less likely to report feeling tired and worn out upon awakening than those receiving trazodone. One recent placebo-controlled study, however, found no differences in sleep outcomes between gabapentin and placebo but patients taking gabapentin remained abstinent longer.68 More controlled studies in alcoholic patients with and without insomnia are necessary to evaluate the efficacy of gabapentin as a sleep aid and/or as an agent to reduce relapse.

Antidepressants

A number of antidepressants have sedative effects. Longo and Johnson69 recommended trazodone or nefazodone as first-line agents for medicating insomnia in substance abusers, but nefazodone is rarely used today because of hepatic failure risk. Trazodone is likely effective acutely in the treatment of depressed patients with insomnia.7073 It has been used safely in several samples of alcoholics.65,74 Liebowitz & El-Mallakh75 posited that trazodone facilitated abstinence in alcoholics by reducing anxiety and insomnia.

Only one controlled study has evaluated the efficacy of trazodone as a hypnotic in alcohol dependent patients. Sixteen patients were randomized to receive 4 weeks of either trazodone (50–200 mg nightly, n=8) or placebo (n=8) following participation in an alcohol detoxification program and two-week washout period. Overnight sleep studies were conducted at baseline, (N1 and N2), the night following the first trazodone or placebo dose (N3), and after four weeks of treatment (N28). The Hamilton Rating Scale for Depression (HRSD) and Clinical Global Impression (CGI) scales were administered at baseline and at post-treatment. Compared to placebo, trazodone reduced wake time after sleep onset (WASO) and improved sleep efficiency with a trend for longer total sleep time on N3. Only WASO improvements were sustained at N28, but CGI and HRSD scores were more improved in the trazodone group.76 Trazodone may improve sleep and other important indicators of daytime functioning in recovering alcoholic patients, but more large scale controlled trials with longer follow-up periods are needed.

Low doses of sedating tricyclic antidepressants (TCAs), such as amitriptyline and doxepin, are used frequently to treat insomnia.53 However, their dosing is complicated by alcohol-induced changes in liver metabolism77 that can result in decreased blood concentrations and efficacy.78 Another disadvantage is that the tricyclic antidepressants have considerable overdose potential in a population that is prone to suicide. SSRIs, another class of antidepressants, can increase the number of awakenings and worsen sleep in both depressed and non-depressed individuals79,80 making them unlikely candidates to treat insomnia. Moreover, studies of alcoholism treatment with TCAs or SSRIs in controlled trials have produced inconsistent results8186 and SSRIs may even worsen drinking outcomes in some patient subgroups.87 The antidepressant mirtazapine was associated with somnolence in controlled clinical trials for major depression and it improves sleep in depressed patients, but has untoward side effects including weight gain.88

Antipsychotics

Quetiapine, an atypical antipsychotic with sedative effects89, has been used to teat insomnia in alcohol dependent patients. Monnelly et al90 found that alcoholic veterans with sleep complaints who received 25–200 mg of quetiapine had more days of abstinence and fewer hospitalizations, suggesting that quetiapine may be associated with improved abstinence through improvements in sleep.90 Unfortunately, sleep was not directly assessed in this study. Moreover, any benefit of quetiapine must be weighed against its potential for akathisia91 and increased periodic limb movements when used to promote sleep.89 Thus, quetiapine should not be a first-line hypnotic for alcoholic patients, but additional studies examining its benefit as a sleep aid are warranted.

Other Hypnotics

Melatonin is a sleep promoting agent that is particularly useful for treating circadian rhythm disorders.92 Given the evidence that melatonin levels are decreased in alcoholic patients,9395 supplemental melatonin should be investigated to treat alcoholic patients with sleep disturbances. Because the manufacturing and quality of melatonin is not currently regulated in the U.S., the melatonin receptor agonist, ramelteon, may be a better candidate for study. Disulfiram causes drowsiness more frequently than placebo,96 but it decreases total REM time97 and is compromised by low compliance rates.96, 98

Nonpharmacological treatments for insomnia

A recent NIH State-of-the-Science conference on the Manifestations and Management of Chronic Insomnia in Adults recently concluded that cognitive-behavioral treatment for insomnia (CBT-I) benefits 70–80% of non-alcoholic insomnia patients and has more sustained benefits than medications.99 The efficacy of CBT-I has been replicated in numerous controlled trials of primary insomnia patients100,101 and more recently in patients with insomnia that is comorbid to chronic pain,102 breast cancer,103105 and hypnotic dependence.106 Four separate meta-analysis found that CBT-I produced medium to large effect sizes for subjective sleep latency, nighttime wakefulness, and sleep efficiency in both young and older patients with insomnia.100,101,107,108 Its efficacy is equivalent to or superior to pharmacological treatments over six to eight weeks,107,109111 with excellent maintenance of therapeutic gains.109 The specific use of CBT-I in alcohol-dependent patients is reviewed below.

CBT-I is a multi-component therapy that includes behavioral and cognitive strategies to consolidate nighttime sleep and improve sleep quality and daytime functioning. Treatment targets the factors that maintain insomnia over time by disrupting the circadian timing system and/or reducing sleep drive. These factors include maladaptive behavioral strategies to compensate for poor sleep (e.g., alcohol use for sleep, napping), efforts to deal with the consequences of insomnia (e.g., excessive caffeine intake), pre-sleep cognitive arousal, and negative sleep-related beliefs and attitudes (e.g., worry about inability to sleep and daytime consequences as a result of sleep loss, unrealistic sleep expectations). Treatment is conducted in individual or group format and usually involves 6 to 8 treatment sessions, although briefer forms of the therapy have shown promise.112 The primary components of CBT-I are briefly described below:

Sleep Restriction

Initially developed in the late 1980s, the goal of sleep restriction is to increase the “drive” or “pressure” to sleep by temporarily restricting sleep to shorter periods of time spent in bed (TIB) and by prohibiting sleep at times outside of this restricted sleep schedule. This technique circumvents the usual compensatory strategy of spending extra time in bed to “catch up” on lost sleep that is used almost universally by patients with insomnia.113 The effect of reducing TIB is to create mild sleep deprivation during the daytime, which helps to consolidate sleep at night. Once sleep is consolidated over a shorter TIB, initially equivalent to the patient’s typical sleep duration, TIB is gradually extended until a sleep/wake schedule that optimizes daytime alertness is achieved.113 Commonly, sleep restriction is implemented along with another behavioral strategy, stimulus control.

Stimulus Control

Another contributor to persistent insomnia is that environmental sleep cues (bed and bedroom) may become associated with wakefulness and with activities and behaviors that are incompatible with sleep, such as reading, watching television, or worrying about the inability to sleep. The major goals of stimulus control therapy are to re-establish the discriminative properties of sleep and sleep-compatible stimuli with the act of sleeping and to stabilize the sleep/wake timing system.114 Patients are provided a set of instructions to follow consistently, shown in Table 1.

Table 1
Stimulus Control Instructions114

Sleep Hygiene Education

Sleep hygiene education provides knowledge about behavioral practices that can help or interfere with nighttime sleep.115 The goal is to increase patients’ awareness of and encourage change in daily activities and environmental factors that may be contributing to the sleep problem. Common topics covered include the detrimental influence of substances such as caffeine, alcohol, and nicotine on sleep, the importance of creating a comfortable, cool, dark, and quiet sleep environment, and the benefits of regular routines, including meal schedules, exercise, and winding down before bed. It is important to note that sleep hygiene in isolation has minimal benefit for patients with persistent sleep difficulties116,117 but it is recommended as part of a multi-component treatment.118,119 Patients need to understand that they may need to engage in changes for a period of time before they will derive sleep benefits. Table 2 highlights some of the most commonly covered sleep hygiene principles.

Table 2
Common sleep hygiene recommendations.

Relaxation Therapy

Relaxation therapy (RT) may be helpful for individuals who exhibit high levels of physiological or cognitive arousal at night and/or during the daytime. There are several RT techniques, some that focus on reducing physiological arousal (e.g., progressive muscle relaxation [PMR], biofeedback) and others that attempt to reduce cognitive arousal (e.g., visualization, thought stopping). Selection of the specific relaxation technique should be determined by the presenting complaints of the patient. Mastery of the relaxation strategies usually requires professional guidance and committed practice over the course of several weeks. Of all the relaxation strategies, PMR and biofeedback have received the most empirical support, demonstrating superiority to placebo, wait-list, and no-treatment controls.120125 Some studies, however, have found relaxation to be less effective than either sleep restriction124,126 or stimulus control,123 thus RT is usually used in conjunction with other CBT-I behavioral components rather than as a stand-alone treatment.115

Cognitive Therapy

Cognitive therapy for insomnia aims to alter dysfunctional beliefs about sleep that contribute to perpetuating sleep problems and helps patients to develop more realistic sleep expectations.115 Dysfunctional beliefs common to insomnia patients (e.g., lack of sleep is totally disabling to functioning) can be addressed using psychoeducational techniques or with a more traditional cognitive therapy model.127 Recent work has found a positive association between a reduction in sleep-related dysfunctional beliefs and attitudes and treatment outcome.128130

There have been comparatively few studies of nonpharmacological sleep treatments in patients recovering from alcohol dependence. Greeff and Conradie131 assessed the benefits of PMR for improving subjective sleep quality in 22 male alcoholic inpatients who met DSM-III-R criteria for an insomnia disorder. Half of the participants received two weeks of daily relaxation training while the other half received no treatment. At post-treatment, the relaxation group reported better sleep quality than the control group on a 10-point rating scale. The study had several methodological limitations, including no screening for occult sleep disorders, poor outcome measure selection, and no active control group.

More recent studies have evaluated the efficacy of CBT-based interventions on insomnia and relapse in alcoholic patients. Currie and colleagues132 randomized sixty alcoholic outpatients (mean age 43.3 ± 10.9 years, 42 men) to individual CBT-I therapy (five sessions over seven weeks), self-help manual with five telephone support calls, or wait-list control. The CBT-I therapy included education about sleep, behavioral therapy (sleep restriction and stimulus control), imagery relaxation, and cognitive therapy. Sleep and drinking outcomes were collected at post-treatment and at 3- and 6-month follow-up with sleep diaries and questionnaires. Treated participants demonstrated greater post-treatment improvements than controls on diary measures of sleep quality, sleep efficiency, number of awakenings, and time to fall asleep. Follow-up assessments at three and six months revealed maintenance of treatment gains. Treatment appeared to have a minimal impact on relapse, however. Conversely, no one relapsed to drinking during a recent 8-week open trial of CBT-I. Moreover, treatment improved sleep quality and important measures of daytime functioning, such as fatigue, mood, and quality of life.133 Finally, use of a six-session group CBT-based treatment focusing on insomnia improved sleep, reduced aggression, and decreased drug use after one year in adolescents who had received treatment for substance abuse.134,135

Taken together, these findings indicate that CBT-I may improve sleep and quality of life of recovering alcoholic patients. The effects of CBT-I on relapse remain to be determined. Studies are needed to compare the efficacy of pharmacological and nonpharmacological interventions for sleep in early alcohol recovery, both alone and in combination. Potential moderators and mediators of treatment outcome, including demographic, clinical, and physiological measures of alcohol dependence need to be considered to identify which alcoholic patients are most in need of adjunctive sleep treatment.

Conclusions and Directions for Future Research

Insomnia and other sleep disturbances are exceedingly common during early recovery from alcohol dependence and likely contribute to relapse in this population. Although sleep improves with continued abstinence, permanent alterations to the sleep centers of the brain from chronic alcohol exposure may produce persistent abnormalities that, in many cases, require independent treatment. When insomnia symptoms persist beyond four weeks and are accompanied by daytime impairments and/or psychological distress, adjunctive sleep treatments should be initiated. Both pharmacological and nonpharmacological treatments are available, but many are either inappropriate or have not been adequately tested in patients with a history of abuse. More well-controlled studies are needed to characterize the phenomenology of sleep during recovery, to determine the efficacy of monotherapy and combined approaches to sleep treatment in alcoholic patients, and to evaluate the impact of such treatments on relapse and recovery in alcohol dependence. Of particular importance are treatment studies that compare treatment-as-usual for addiction with and without adjunctive pharmacological and nonpharmacological insomnia treatments to determine the relative importance of focusing on sleep problems during alcohol recovery.

Acknowledgments

Research Support: National Institute on Alcohol Abuse and Alcoholism (R21 AA014408, T32 AA07477, and 2K24 AA00304)

REFERENCES

1. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry. 1985;42:225–232. [PubMed]
2. Roth T, Ancoli-Israel S. Daytime consequences and correlates of insomnia in the United States: Results of the 1991 National Sleep Foundation Survey. II. Sleep. 1999;22:S354–S358. [PubMed]
3. Shochat T, Umphress J, Israel AG, Ancoli-Israel S. Insomnia in primary care patients. Sleep. 1999;22 Suppl 2:S359–S365. [PubMed]
4. National Sleep Foundation. Washington, DC: 2005. 2005 Sleep in America Poll.
5. Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA. 1989;262:1479–1484. [PubMed]
6. Oyahon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Medicine Reviews. 2002;6:97–111. [PubMed]
7. Mello NK, Mendelson JH. Behavioral studies of sleep patterns in alcoholics during intoxication and withdrawal. J Pharmacol Exp Ther. 1970;175:94–112. [PubMed]
8. Baekeland F, Lundwall L, Shanahan TJ, Kissin B. Clinical correlates of reported sleep disturbance in alcoholics. Q J Stud Alcohol. 1974;35:1230–1241. [PubMed]
9. Rundell OH, Williams HL, Lester BK. Sleep in alcoholic patients: longitudinal findings. Adv Exp Med Biol. 1977;85B:389–402. [PubMed]
10. Caetano R, Clark CL, Greenfield TK. Prevalence, trends, and incidence of alcohol withdrawal symptoms: Analysis of general population and clinical samples. Alcohol Health and Research World. 1998;22:73–79. [PubMed]
11. Foster JH, Marshall EJ, Peters TJ. Application of a quality of life measure, the life situation survey (LSS), to alcohol-dependent subjects in relapse and remission. Alcohol Clin Exp Res. 2000;24:1687–1692. [PubMed]
12. Brower KJ, Aldrich MS, Robinson EAR, Zucker RA, Greden JF. Insomnia, Self-Medication, and Relapse to Alcoholism. Am J Psychiatry. 2001;158:399–404. [PMC free article] [PubMed]
13. Brower KJ. Alcohol's effects on sleep in alcoholics. Alcohol Research and Health. 2001;25:110–125. [PMC free article] [PubMed]
14. Cohn TJ, Foster JH, Peters TJ. Sequential studies of sleep disturbance and quality of life in abstaining alcoholics. Addiction Biology. 2003;8:455–462. [PubMed]
15. Foster JH, Peters TJ. Impaired sleep in alcohol misusers and dependent alcoholics and the impact upon outcome. Alcohol Clin Exp Res. 1999;23:1044–1051. [PubMed]
16. Brower KJ, Aldrich MS, Hall JM. Polysomnographic and subjective sleep predictors of alcoholic relapse. Alcoholism: Clinical and Experimental Research. 1998;22:1864–1871. [PubMed]
17. Johnson EO, Roehrs T, Roth T, Breslau N. Epidemiology of alcohol and medication as aids to sleep in early adulthood. Sleep. 1998;21:178–186. [PubMed]
18. Weissman MM, Greenwald S, Nino-Murcia G, Dement WC. The morbidity of insomnia uncomplicated by psychiatric disorders. General Hospital Psychiatry. 1997;19:245–250. [PubMed]
19. Crum RM, Storr CL, Chan Y-F, Ford DE. Sleep Disturbance and Risk for Alcohol-Related Problems. Am J Psychiatry. 2004;161:1197–1203. [PubMed]
20. Crum RM, Ford DE, Storr CL, Chan Y-F. Association of sleep disturbance with chronicity and remission of alcohol dependence: Data from a population-based prospective study. Alcoholism: Clinical and Experimental Research. 2004;28:1533–1540. [PubMed]
21. Wong MM, Brower KJ, Fitzgerald HE, Zucker RA. Sleep problems in early childhood and early onset of alcohol and other drug use in adolescence. Alcoholism: Clinical and Experimental Research. 2004;28:578–587. [PubMed]
22. Benca RM. Sleep in psychiatric disorders. Neurologic Clinics. 1996;14:739–764. [PubMed]
23. Alling C, Balldin J, Bokstrom K, Gottfries CG, Karlsson I, Langstrom G. Studies on duration of a late recovery period after chronic abuse of ethanol. A cross-sectional study of biochemical and psychiatric indicators. Acta Psychiatr Scand. 1982;66:384–397. [PubMed]
24. Buysse DJ, Reynolds CF, III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Research. 1989;28:193–213. [PubMed]
25. Gann H, Feige B, Hohagen F, van Calker D, Geiss D, Dieter R. Sleep and the cholinergic Rapid Eye Movement sleep induction test in patients with primary alcohol dependence. Biological Psychiatry. 2001;50:383–390. [PubMed]
26. Carskadon MA, Dement WC. Normal human sleep: An overview. In: Kryger MH, Roth T, Dement WC, editors. Principles and Practice of Sleep Medicine. Philadelpha: W.B. Saunders Company; 2000. pp. 15–25.
27. Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: Developing normative sleep values across the human lifespan. Sleep. 2004;27:1255–1273. [PubMed]
28. Adamson J, Burdick JA. Sleep of dry alcoholics. Arch Gen Psychiatry. 1973;28:146–149. [PubMed]
29. Gross MM, Goodenough DR, Nagarajan M, Hastey JM. Sleep changes induced by 4 and 6 days of experimental alcoholization and withdrawal in humans. In: Gross MM, editor. Alcohol Intoxication and Withdrawal: Experimental Studies I, Advances in Experimental Medicine and Biology. Vol. 35. New York: Plenum Press; 1973. pp. 291–294.
30. Johnson LC, Burdick JA, Smith J. Sleep during alcohol intake and withdrawal in the chronic alcoholic. Arch Gen Psychiatry. 1970;22:406–418. [PubMed]
31. Lester BK, Rundell OH, Cowden LC, Williams HL. Chronic alcoholism, alcohol and sleep. In: Gross MM, editor. Alcohol Intoxication and Withdrawal: Experimental Studies 1. Vol. 35. New York, NY: Plenum Press; 1973. pp. 261–280.
32. Wagman AM, Allen RP. Effects of alcohol ingestion and abstinence on slow wave sleep of alcoholics. Adv Exp Med Biol. 1975;59:453–466. [PubMed]
33. Gillin JC, Smith TL, Irwin M, Kripke DF, Schuckit M. EEG sleep studies in "pure" primary alcoholism during subacute withdrawal: relationships to normal controls, age, and other clinical variables. Biol Psychiatry. 1990;27:477–488. [PubMed]
34. Le Bon O, Verbanck P, Hoffmann G, Murphy JR, Staner L, De Groote D, Mampunza S, Den Dulk A, Vacher C, Kornreich C, Pelc I. Sleep in detoxified alcoholics: impairment of most standard sleep parameters and increased risk for sleep apnea, but not for myoclonias--a controlled study. J Stud Alcohol. 1997;58:30–36. [PubMed]
35. Gann H, Van Calker D, Feige B, Cloot O, Brück D, Berger M, Riemann D. Polysomnographic comparison between patients with primary alcohol dependency during subacute withdrawal and patients with major depression. European Archives of Psychiatry and Clinical Neuroscience. 2004;254:263–271. [PubMed]
36. Brower KJ, Hall JM. Effects of age and alcoholism on sleep: a controlled study. J Stud Alcohol. 2001;62:335–343. [PMC free article] [PubMed]
37. Irwin M, Miller C, Gillin JC, Demodena A, Ehlers CL. Polysomnographic and spectral sleep EEG in primary alcoholics: an interaction between alcohol dependence and African-American ethnicity. Alcohol Clin Exp Res. 2000;24:1376–1384. [PubMed]
38. Gillin JC, Smith TL, Irwin M, Kripke DF, Brown S, Schuckit M. Short REM latency in primary alcoholic patients with secondary depression. Am J Psychiatry. 1990;147:106–109. [PubMed]
39. Williams HL, Rundell OH., Jr Altered sleep physiology in chronic alcoholics: reversal with abstinence. Alcohol Clin Exp Res. 1981;5:318–325. [PubMed]
40. Drummond SPA, Gillin JC, Smith TL, DeModena A. The sleep of abstinent pure primary alcoholic patients: Natural course and relationship to relapse. Alcoholism: Clinical and Experimental Research. 1998;22:1796–1802. [PubMed]
41. Skoloda TE, Alterman AI, Gottheil E. Sleep quality reported by drinking and non-drinking alcoholics. In: Gottheil EL, editor. Addiction research and treatment : converging trends : proceedings of the First Annual Coatesville-Jefferson Conference on Addiction; Pergamom Press; Elmsford, NY. 1979. pp. 102–112.
42. Foster JH, Marshall EJ, Peters TJ. Predictors of relapse to heavy drinking in alcohol dependent subjects following alcohol detoxification - The role of quality of life measures, ethnicity, social class, cigarettes and drug use. Addiction Biology. 1998;3:333–343.
43. Brower KJ. Insomnia, alcoholism and relapse. Sleep Medicine Reviews. 2003;7:523–539. [PubMed]
44. Vitiello MV. Sleep, alcohol, and alcohol abuse. Addiction Biology. 1997;2:151–158.
45. Allen RP, Wagman AM, Funderburk FR. Slow wave sleep changes: alcohol tolerance and treatment implications. Adv Exp Med Biol. 1977;85A:629–640. [PubMed]
46. Aldrich MS, Hall JM, Eiser AS, Kroll P, Brower K, Shipley JE. Slow wave sleep decrement and relapse tendency in alcoholics in treatment. Sleep Research. 1994;23:185.
47. Gillin JC, Smith TL, Irwin M, Butters N, Demodena A, Schuckit M. Increased pressure for rapid eye movement sleep at time of hospital admission predicts relapse in nondepressed patients with primary alcoholism at 3-month follow-up. Arch Gen Psychiatry. 1994;51:189–197. [PubMed]
48. Clark CP, Gillin JC, Golshan S, Demodena A, Smith TL, Danowski S, Irwin M, Schuckit M. Increased REM sleep density at admission predicts relapse by three months in primary alcoholics with a lifetime diagnosis of secondary depression. Biol Psychiatry. 1998;43:601–607. [PubMed]
49. Friedmann PD, Herman DS, Freedman S, Lemon SC, Ramsey S, Stein MD. Treatment of sleep disturbance in alcohol recovery: A national survey of addiction medicine physicians. J Addict Dis. 2003;22:91–103. [PMC free article] [PubMed]
50. Roehrs T, Roth T. Hypnotics: an update. Current Neurology and Neuroscience Reports. 2003;3:181–184. [PubMed]
51. Aubin H-J, Goldenberg F, Benoit O, Gillet C, Roullet-Volmi M-C, Barrucand D. Effects of tetrabamate and of diazepam on sleep polygraphy during subacute withdrawal in alcohol-dependent patients. Human Psychopharmacology. 1994;9:191–195.
52. Mendelson WB, Roth T, Cassella J, Roehrs T, Walsh JK, Woods JH, Buysse DJ, Meyer RE. The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit Meeting Symposium. Sleep Medicine Reviews. 2004;8:7–17. [PubMed]
53. Graham AW. Sleep disorders. In: Graham AW, Schultz T, editors. Principles of Addiction Medicine. Chevy Chase, MD: American Society of Addiction Medicine; 1998. pp. 793–808.
54. Ciraulo DA, Nace EP. Benzodiazepine treatment of anxiety or insomnia in substance abuse patients. The American Journal on Addictions. 2000;9:276–284. [PubMed]
55. Hajak G, Muller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction. 2003;98:1371–1378. [PubMed]
56. Johnson B, Longo LP. Considerations in the physician's decision to prescribe benzodiazepines to patients with addiction. Psychiatric Annals. 1998;28:160–165.
57. Kranzler HR. Evaluation and treatment of anxiety symptoms and disorders in alcoholics. Journal of Clinical Psychiatry. 1996;57:15–21. [PubMed]
58. Schuckit MA. Recent developments in the pharmacotherapy of alcohol dependence. Journal of Consulting and Clinical Psychology. 1996;64:669–676. [PubMed]
59. Swift RM. Pharmacologic treatment for drug and alcohol dependence: experimental and standard therapies. Psychiatric Annals. 1998;28:697–702.
60. Achermann P, Borbély AA. Dynamics of EEG slow wave activity during physiological sleep after administration of benzodiazepine hypnotics. Human Neurobiology. 1987;6:203–210. [PubMed]
61. Johnson BA, Swift RM, Ait-Daoud N, DiClemente CC, Javors MA, Malcolm R., Jr Development of novel pharmacotherapies for the treatment of alcohol dependence: Focus on antiepileptics. Alcoholism: Clinical and Experimental Research. 2004;28:295–301. [PubMed]
62. Malcolm RH, Myrick H, Roberts J, Wang W, Anton RF. The differential effects of medication on mood, sleep disturbance, and work ability in outpatient alcohol detoxification. American Journal of Addictions. 2002;11:141–150. [PubMed]
63. LaRoche S, Helmers S. The new antiepileptic drugs. JAMA. 2004;291:605–614. [PubMed]
64. Karam-Hage M, Brower KJ. Gabapentin treatment for insomnia associated with alcohol dependence. Am J Psychiatry. 2000;157:151. [PubMed]
65. Karam-Hage M, Brower KJ. Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic patients. Psychiatry and Clinical Neurosciences. 2003;57:542–544. [PMC free article] [PubMed]
66. Rosenberg KP. Gabapentin for chronic insomnia. The American Journal on Addictions. 2003;12 [PubMed]
67. Jenkins CD, Stanton BA, Niemcryk SJ, Rose RM. A scale for the estimation of sleep problems in clinical research. Journal of Clinical Epidemiology. 1988;41:313–321. [PubMed]
68. Brower KJ, Kim HM, Karam-Hage MA, Zucker RA, Greden JF. A double-blind randomized clinical trial of gabapentin vs. placebo for treating alcohol dependence. Biological Psychiatry. 2003;53:845–855.
69. Longo LP, Johnson B. Treatment of insomnia in substance abusing patients. Psychiatric Annals. 1998;28:154–159.
70. Armitage R. The effects of antidepressants on sleep in patients with depression. Canadian Journal of Psychiatry. 2000;45:803–809. [PubMed]
71. Mendelson WB. A review of the evidence for the efficacy and safety of trazodone for insomnia. Journal of Clinical Psychiatry. 2005;66:469–476. [PubMed]
72. Kaynak H, Kaynak D, Gozukirmizi E, Guilleminault C. The effects of trazodone on sleep in patients treated with stimulant antidepressants. Sleep Medicine. 2004;5:15. [PubMed]
73. Nierenberg AA, Adler LA, Peselow E, Zornberg G, Rosenthal M. Trazadone for antidepressant-associated insomnia. American Journal of Psychiatry. 1994;151:1069–1072. [PubMed]
74. Janiri L, Hadjichristos A, Buonanno A, Rago R, Mannelli P, de Risio S. Adjuvant trazodone in the treatment of alcoholism: an open study. Alcohol & Alcoholism. 1998;33:362–365. [PubMed]
75. Liebowitz NR, El-Mallakh RS. Trazodone for the treatment of anxiety symptoms in substance abusers. Journal of Clinical Psychopharmacology. 1989;9:449–450. [PubMed]
76. Le Bon O, Murphy JR, Staner L, Hoffmann G, Kormoss N, Kentos M, Dupont P, Lion K, Pelc I, Verbanck P. Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations. Journal of Clinical Psychopharmacology. 2003;23:377–383. [PubMed]
77. Ciraulo DA, Sands BF, Shader RI. Critical review of liability for benzodiazepine abuse among alcoholics. American Journal of Psychiatry. 1988;145:1501–1506. [PubMed]
78. Mason BJ. Dosing issues in the pharmacotherapy of alcoholism. Alcoholism: Clinical and Experimental Research. 1996;20:10A–16A. [PubMed]
79. Gillin JC, Rapaport M, Erman MK, Winokur A, Albala BJ. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: A double-blind, 8-week clinical trial. Journal of Clinical Psychiatry. 1997;58:185–192. [PubMed]
80. Sharpley AL, Williamson DJ, Attenburrow MEJ, Pearson G, Sargent P, Cowen PJ. The effects of paroxetine and nefazodone on sleep: A placebo controlled trial. Psychopharmacology. 1996;126:50–54. [PubMed]
81. Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Perel JM, Thase ME, A B. Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. Arch Gen Psychiatry. 1997;54:700–705. [PubMed]
82. Kranzler HR, Burleson JA, Korner P, Del Boca FK, Bohn MJ, Brown J, Liebowitz N. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. American Journal of Psychiatry. 1995;152:391–397. [PubMed]
83. Kranzler HR, Mueller T, Cornelius J, Pettinati HM, Moak D, Martin PR, Anthenelli R, Brower KJ. Sertraline treatment of co-occurring alcohol dependence and major depression. Journal of Clinical Psychopharmacology. 2006;26:13–20. [PubMed]
84. McBride WJ, Le AD, Noronha A. Central nervous system mechanisms in alcohol relapse. Alcoholism: Clinical and Experimental Research. 2002;26:280–286. [PubMed]
85. Moak DH, Anton RF, Latham PK, Voronin KE, Waid RL, Durazo-Arvizu R. Sertraline and cognitive behavioral therapy for depressed alcoholics: results of a placebo-controlled trial. Journal of Clinical Psychopharmacology. 2003;23:553–562. [PubMed]
86. Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA. 2004;291:1887–1896. [PubMed]
87. Dundon W, Lynch KG, Pettinati HM, Lipkin C. Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy. Alcoholism: Clinical and Experimental Research. 2004;28:1065–1073. [PMC free article] [PubMed]
88. Winokur A, Sateia MJ, Hayes JB, Bayles-Dazet W, MacDonald MM, Gary KA. Acute effects of mirtazapine on sleep continuity and sleep architecture in depressed patients: a pilot study. Biological Psychiatry. 2000;48:75–78. [PubMed]
89. Cohrs S, Rodenbeck A, Guan Z, Pohlmann K, Jordan W, Meier A, Ruther E. Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology. 2004;174:421–429. [PubMed]
90. Monnelly EP, Ciraulo DA, Knapp C, LoCastro J, Sepulvda I. Quetiapine for treatment of alcohol dependence. Journal of Clinical Psychopharmacology. 2004;24:532–535. [PubMed]
91. Catalano G, Grace JW, Catalano MC, Morales MJ, Cruse LM. Acute akathisia associated with quetiapine use. Psychosomatics. 2005;46:291–301. [PubMed]
92. Cajochen C, Krauchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. Journal of Neuroendocrinology. 2003;15:432–437. [PubMed]
93. Kühlwein E, Hauger RL, Irwin MR. Abnormal nocturnal melatonin secretion and disordered sleep in abstinent alcoholics. Biological Psychiatry. 2003;54:1437–1443. [PubMed]
94. Schmitz MM, Sepandj A, Pichler PM, Rudas S. Disrupted melatonin-secretion during alcohol withdrawal. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 1996;20:983. [PubMed]
95. Wetterberg L, Aperia B, Gorelick DA, Gwirtzman HE, McGuire MT, Serafetinides EA, A Y. Age, alcoholism and depression are associated with low levels of urinary melatonin. Journal of Psychiatry and Neuroscience. 1992;17:215–224. [PMC free article] [PubMed]
96. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD, Iber FL, James KE, Lacoursiere RB, Lee KK, Lowenstam I, et al. A Veterans Administration cooperative study. Disulfiram treatment of alcoholism. JAMA. 1986;256:1449–1455. [PubMed]
97. Snyder S, Karacan I, Salis PJ. Effects of disulfiram on the sleep of chronic alcoholics. Currents in Alcoholism. 1981;8:159–166. [PubMed]
98. Fuller RK, Gordis E. Does disulfiram have a role in alcoholism treatment today? Addiction. 2004;99:21–24. [PubMed]
99. NIH State-of-the-Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults; NIH Consens Sci Statements; 2005. Jun 13–15, pp. 1–30. [PubMed]
100. Morin CM, Culbert JP, Schwartz SM. Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy. Am J Psychiatry. 1994;151:1172–1180. [PubMed]
101. Murtagh DRR, Greenwood KM. Identifying effective psychological treatments for insomnia: A meta-analysis. Journal of Consulting and Clinical Psychology. 1995;63:79–89. [PubMed]
102. Currie SR, Wilson KG, Pontefract AJ, deLaplante L. Cognitive-behavioral treatment of insomnia secondary to chronic pain. J Consult Clin Psychol. 2000;68:407–416. [PubMed]
103. Davidson JR, Waisberg JL, Brundage MD, MacLean AW. Nonpharmacologic group treatment of insomnia: a preliminary study with cancer survivors. Psycho-Oncology. 2001;10:389–397. [PubMed]
104. Quesnel C, Savard J, Simard S, Ivers H, Morin CM. Efficacy of cognitive-behavioral therapy for insomnia in women treated for nonmetastatic breast cancer. J Consult Clin Psychol. 2003;71:189–200. [PubMed]
105. Savard J, Simard S, Ivers H, Morin CM. Randomized Study on the Efficacy of Cognitive-Behavioral Therapy for Insomnia Secondary to Breast Cancer, Part I: Sleep and Psychological Effects. J Clin Oncol. 2005;23:6083–6096. [PubMed]
106. Morin CM, PhD, Bastien C, PhD, Guay B, MD, Radouco-Thomas M, MD, Leblanc J, BCPP, Vallieres A., PhD Randomized Clinical Trial of Supervised Tapering and Cognitive Behavior Therapy to Facilitate Benzodiazepine Discontinuation in Older Adults With Chronic Insomnia. American Journal of Psychiatry. 2004;161:332–342. [PubMed]
107. Smith MT, Perlis ML, Park A, Smith MS, Pennington J, Giles DE, Buysse DJ. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry. 2002;159:5–11. [PubMed]
108. Irwin MR, Cole JC, Nicassio PM. Comparative meta-analysis of behavioral interventions for insomnia and their efficacy in middle-aged adults and in older adults 55+ years of age. Health Psychology. 2006;25:3–14. [PubMed]
109. Morin CM, Colecchi C, Stone J, Sood R, Brink D. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA. 1999;281:991–999. [PubMed]
110. Jacobs GD, Pace-Schott E, Stickgold R, Otto MW. Cognitive behavior therapy and pharmacotherapy for insomnia. Archives of Internal Medicine. 2004;164:1888–1896. [PubMed]
111. Sivertsen B, Omvik S, Pallesen S, Bjorvatn B, Havik OE, Kvale G, Nielsen GH, Nordhus IH. Cognitive Behavioral Therapy vs Zopiclone for Treatment of Chronic Primary Insomnia in Older Adults: A Randomized Controlled Trial. JAMA. 2006;295:2851–2858. [PubMed]
112. Edinger JD, Sampson WS. A primary care "friendly" cognitive behavioral insomnia therapy. Sleep. 2002;26:177–182. [PubMed]
113. Spielman AJ, Saskin P, Thorpy MJ. Treatment of chronic insomnia by restriction of time in bed. Sleep. 1987;10:45–56. [PubMed]
114. Bootzin RR, Nicassio PM. Behavioral treatments for insomnia. In: Hersen M, Eissler R, Miller P, editors. Progress in Behavior Modification. Vol. 6. New York, NY: Academic Press; 1978. pp. 1–45.
115. Morin CM. Insomnia: Psychological assessment and management. New York: The Guilford Press; 1993.
116. Engle-Friedman M, Bootzin RR, Hazlewood L, Tsao C. An evaluation of behavioral treatments for insomnia in the older adult. J Clin Psychol. 1992;48:77–90. [PubMed]
117. Guilleminault C, Clerk A, Black J, Labanowski M, Pelayo R, Claman D. Nondrug treatment trials in psychophysiological insomnia. Arch Intern Med. 1995;155:838–844. [PubMed]
118. Morin CM, Hauri PJ, Espie CA, Spielman AJ, Buysse DJ, Bootzin RR. Nonpharmacologic treatment of chronic insomnia. An American Academy of Sleep Medicine review. Sleep. 1999;22:1134–1156. [PubMed]
119. Chesson AL, Jr, Anderson WC, Littner M, Davila D, Hartse K, Johnson S, Wise M, Rafecas J. Practice parameters for the nonpharmacologic treatment of chronic insomnia. Sleep. 1999;22:1128–1133. [PubMed]
120. Nicassio PM, Bootzin R. A comparison of progressive relaxation and autogenic training as treatments for insomnia. Journal of Abnormal Psychology. 1974;83:253–260. [PubMed]
121. Nicassio PM, Boylan MB, McCabe TW. Progressive relaxation, biofeedback and biofeedback placebo in the treatment of sleep onset insomnia. British Journal of Medical Psychology. 1982;55:159–166. [PubMed]
122. Sanavio E. Pre-sleep cognitive intrusions and treatment of onset-insomnia. Behaviour Research and Therapy. 1988;26:451–459. [PubMed]
123. Espie CA, Lindsay WR, Brooks DN, Hood E, Turvey T. A controlled comparative investigation of psychological treatments for chronic sleep-onset insomnia. Behaviour Research and Therapy. 1989;27:79–88. [PubMed]
124. Friedman L, Bliwise DL, Yesavage JA, Salom SR. A preliminary study comparing sleep restriction and relaxation treatments for insomnia in older adults. Journal of Gerontology. 1991;46:1–8. [PubMed]
125. Lichstein KL, Johnson RS. Relaxation for insomnia and hypnotic medication use in older women. Psychology and Aging. 1993;8:103–111. [PubMed]
126. Lichstein KL, Riedel BW, Wilson NM, Lester KW, Aguillard RN. Relaxation and sleep compression for late-life insomnia: a placebo- controlled trial. J Consult Clin Psychol. 2001;69:227–239. [PubMed]
127. Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive therapy of depression. New York: The Guilford Press; 1979.
128. Edinger JD, Wohlgemuth WK, Radtke RA, Marsh GR, Quillian RE. Does cognitivebehavioral insomnia therapy alter dysfunctional beliefs about sleep? Sleep. 2001;24:591–599. [PubMed]
129. Morin CM, Blais F, Savard J. Are changes in beliefs and attitudes about sleep related to sleep improvements in the treatment of insomnia? Behav Res Ther. 2002;40:741–752. [PubMed]
130. Harvey L, Inglis SJ, Espie CA. Insomniacs' reported use of CBT components and relationship to long-term clinical outcome. Behaviour Research and Therapy. 2002;40:75–83. [PubMed]
131. Greeff AP, Conradie WS. Use of progressive relaxation training for chronic alcoholics with insomnia. Psychol Rep. 1998;82:407–412. [PubMed]
132. Currie SR, Clark S, Hodgins DC, el-Guebaly N. Randomized controlled trial of brief cognitive-behavioural interventions for insomnia in recovering alcoholics. Addiction. 2004;99:1121–1132. [PubMed]
133. Arnedt JT, Conroy D, Rutt J, Aloia MS, Brower KJ, Armitage R. An open trial of cognitive-behavioral treatment for insomnia comorbid with alcohol dependence. Sleep Medicine. in press. [PubMed]
134. Bootzin RR, Stevens SJ. Adolescents, substance abuse, and the treatment of insomnia and daytime sleepiness. Clinical Psychology Review. 2005;25:629–644. [PubMed]
135. Haynes PL, Bootzin RR, Smith L, Cousins J, Cameron M, Stevens S. Sleep and aggression in substance-abusing adolescents: Results from an integrative behavioral sleep-treatment pilot program. Sleep. 2006;29:512–520. [PubMed]